Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB


News SummaryMost relevantAll newsSector newsTweets 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
01/28/2013 | 01:13pm CET
   By Tess Stynes and Melodie Warner 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOGEN INC
04:01pDJBIOGEN : Reaches Settlement and License Agreement for MS Drug
01:31p BIOGEN : and Forward Pharma Agree to Enter into Settlement and License Agreement
01/12 BIOGEN : Spin-off Bioverativ Commences When-Issued Trading of Common Stock
01/05 BIOGEN : exercises option to enter into exclusive, worldwide License Agreement f..
01/02 New drug approvals fall to six-year low in 2016
2016 BIOGEN : Announces Effectiveness of Bioverativ Form 10 Registration Statement
2016 BIOGEN : and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CE..
2016 BIOGEN : Names Michel Vounatsos Chief Executive Officer
2016 BIOGEN : Announces that Bioverativ will Host an Investor Day on January 6, 2017
2016 BIOGEN : Board of Directors Approves Separation of Bioverativ and Declares Speci..
More news
Sector news : Biopharmaceuticals
08:40aDJASTRAZENECA : Sets New Deadlines for MYSTIC Trial
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
More sector news : Biopharmaceuticals
News from SeekingAlpha
08:26a Biogen to pay Forward Pharma $1.25B in patent infringement case related to MS..
01/16 PFIZER : 2 Risks Every Shareholder Should Be Aware Of
01/16 WEEK 3 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
01/13 2016 : A Record Year
Financials ($)
Sales 2016 11 522 M
EBIT 2016 6 056 M
Net income 2016 4 127 M
Debt 2016 578 M
Yield 2016 -
P/E ratio 2016 15,19
P/E ratio 2017 14,76
EV / Sales 2016 5,43x
EV / Sales 2017 5,14x
Capitalization 61 954 M
More Financials
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 341 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC0.41%61 954
CSL LIMITED0.67%34 476
GRIFOLS SA1.75%13 046
More Results